“FDA Approves World’s First RSV Vaccine for Older Adults”

Food and Drug Administration (FDA)FDA) The United States, in a publication on its official website, announced that the world’s first vaccine aimed at combating respiratory syncytial virus, or RSV, has been approved by the agency.

It is noted that the established company GSK a vaccine called Arexvy can be used to prevent the disease in people over the age of 60 years. IN FDA claim that vaccination reduced the risk of infection by 82.6%, and the risk of severe disease – up to 94.1%.

It is stated that the vaccine GSK is aimed at producing antibodies to the F-protein of the virus, which promotes the formation of syncytium, provokes bronchial hyperreactivity and blocks the airways, which, in turn, causes bronchitis and pneumonia.

It is assumed that another vaccine against this disease with a similar principle of action, the developer of which is Pfizermay be approved FDA already this month.